QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
NASDAQ:MASI

Masimo Stock Forecast, Price & News

$280.49
+3.52 (+1.27%)
(As of 12/6/2021 04:00 PM ET)
Add
Compare
Today's Range
$274.70
$281.89
50-Day Range
$266.41
$303.29
52-Week Range
$205.10
$305.21
Volume
237,948 shs
Average Volume
295,463 shs
Market Capitalization
$15.49 billion
P/E Ratio
69.95
Dividend Yield
N/A
Beta
0.73
30 days | 90 days | 365 days | Advanced Chart
Receive MASI News and Ratings via Email

Sign-up to receive the latest news and ratings for Masimo and its competitors with MarketBeat's FREE daily newsletter.


Masimo logo

About Masimo

Masimo Corp. is a medical technology company, which develops, manufactures and markets non invasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Headlines

Masimo's (MASI) Rad-G Clinical Study Trial Outcome Favorable
November 30, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:MASI
CUSIP
57479510
Employees
5,300
Year Founded
1989

Sales & Book Value

Annual Sales
$1.14 billion
Cash Flow
$4.30 per share
Book Value
$26.59 per share

Profitability

Net Income
$240.30 million
Pretax Margin
21.91%

Debt

Price-To-Earnings

Miscellaneous

Free Float
50,197,000
Market Cap
$15.49 billion
Optionable
Optionable

Company Calendar

Last Earnings
10/25/2021
Today
12/06/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/22/2022

Social Links


MarketRank

Overall MarketRank

1.92 out of 5 stars

Medical Sector

487th out of 1,390 stocks

Electromedical Equipment Industry

11th out of 29 stocks

Analyst Opinion: 1.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -












Masimo (NASDAQ:MASI) Frequently Asked Questions

Is Masimo a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Masimo in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Masimo stock.
View analyst ratings for Masimo
or view top-rated stocks.

How has Masimo's stock been impacted by Coronavirus?

Masimo's stock was trading at $182.64 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MASI stock has increased by 53.6% and is now trading at $280.49.
View which stocks have been most impacted by COVID-19
.

When is Masimo's next earnings date?

Masimo is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Masimo
.

How were Masimo's earnings last quarter?

Masimo Co. (NASDAQ:MASI) announced its quarterly earnings results on Monday, October, 25th. The medical equipment provider reported $0.94 earnings per share for the quarter, beating analysts' consensus estimates of $0.91 by $0.03. The medical equipment provider earned $307.40 million during the quarter, compared to the consensus estimate of $295.79 million. Masimo had a trailing twelve-month return on equity of 15.56% and a net margin of 19.23%. The company's revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.80 earnings per share.
View Masimo's earnings history
.

What guidance has Masimo issued on next quarter's earnings?

Masimo issued an update on its FY 2021 earnings guidance on Tuesday, November, 2nd. The company provided earnings per share guidance of $3.880-$3.880 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.790. The company issued revenue guidance of $1.23 billion-$1.23 billion, compared to the consensus revenue estimate of $1.22 billion.

What price target have analysts set for MASI?

3 Wall Street analysts have issued 1 year price targets for Masimo's shares. Their forecasts range from $285.00 to $330.00. On average, they expect Masimo's share price to reach $308.33 in the next twelve months. This suggests a possible upside of 9.9% from the stock's current price.
View analysts' price targets for Masimo
or view top-rated stocks among Wall Street analysts.

Who are Masimo's key executives?

Masimo's management team includes the following people:
  • Joe E. Kiani, Chairman & Chief Executive Officer
  • Bilal Muhsin, Chief Operating Officer
  • Micah Young, Chief Financial Officer & Executive Vice President (LinkedIn Profile)
  • Yongsam Lee, Chief Information Officer & Executive VP
  • Anand Sampath, Executive VP-Operations & Clinical Research

What is Joe E. Kiani's approval rating as Masimo's CEO?

136 employees have rated Masimo CEO Joe E. Kiani on Glassdoor.com. Joe E. Kiani has an approval rating of 90% among Masimo's employees.

What other stocks do shareholders of Masimo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Masimo investors own include NVIDIA (NVDA), Netflix (NFLX), Shopify (SHOP), Okta (OKTA), PayPal (PYPL), Alibaba Group (BABA), Mastercard (MA), Trade Desk (TTD), Walt Disney (DIS) and Twilio (TWLO).

What is Masimo's stock symbol?

Masimo trades on the NASDAQ under the ticker symbol "MASI."

Who are Masimo's major shareholders?

Masimo's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (16.11%), Ownership Capital B.V. (3.64%), Invesco Ltd. (2.10%), Massachusetts Financial Services Co. MA (1.53%), RTW Investments LP (1.51%) and Credit Suisse AG (1.42%). Company insiders that own Masimo stock include Adam Mikkelson, Anand Sampath, Bilal Muhsin, Craig B Reynolds, H Michael Cohen, Joe E Kiani, Jon Coleman, Micah W Young, Ramshorst David J Van, Sanford Fitch, Steven Barker, Thomas Samuel Mcclenahan and Yongsam Lee.
View institutional ownership trends for Masimo
.

Which major investors are selling Masimo stock?

MASI stock was sold by a variety of institutional investors in the last quarter, including Neuberger Berman Group LLC, Eagle Asset Management Inc., Credit Suisse AG, Citigroup Inc., Schroder Investment Management Group, Ensemble Capital Management LLC, UBS Group AG, and Goldman Sachs Group Inc.. Company insiders that have sold Masimo company stock in the last year include Anand Sampath, Craig B Reynolds, Joe E Kiani, and Micah W Young.
View insider buying and selling activity for Masimo
or view top insider-selling stocks.

Which major investors are buying Masimo stock?

MASI stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Sumitomo Mitsui Trust Holdings Inc., Martin Currie Ltd., Mitsubishi UFJ Trust & Banking Corp, Ownership Capital B.V., Morgan Stanley, Eversept Partners LP, and BNP Paribas Asset Management Holding S.A..
View insider buying and selling activity for Masimo
or or view top insider-buying stocks.

How do I buy shares of Masimo?

Shares of MASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Masimo's stock price today?

One share of MASI stock can currently be purchased for approximately $280.49.

How much money does Masimo make?

Masimo has a market capitalization of $15.49 billion and generates $1.14 billion in revenue each year. The medical equipment provider earns $240.30 million in net income (profit) each year or $4.01 on an earnings per share basis.

How many employees does Masimo have?

Masimo employs 5,300 workers across the globe.

When was Masimo founded?

Masimo was founded in 1989.

What is Masimo's official website?

The official website for Masimo is www.masimo.com.

Where are Masimo's headquarters?

Masimo is headquartered at 52 DISCOVERY, IRVINE CA, 92618.

How can I contact Masimo?

Masimo's mailing address is 52 DISCOVERY, IRVINE CA, 92618. The medical equipment provider can be reached via phone at (949) 297-7000, via email at [email protected], or via fax at 949-297-7001.


This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.